

Impact of TME on the Efficacy of PD-L1 Blockade in NSCLC

Huixuan Qi

Qilu Medical University, School of Public Health, Zibo, Shandong, 255300, China
Corresponding author: qihuixuan@qlmu.edu.cn

Abstract:

Non-small cell lung cancer (NSCLC) is one of the most common cancer types worldwide, and treatment options are complex and individualized. Immune checkpoint inhibitors, particularly therapeutic strategies targeting the PD-1/PD-L1 pathway, have resulted in significant prognostic improvements for some patients. The tumor microenvironment (TME) plays an important role in affecting the therapeutic effect of NSCLC, but its mechanism still needs to be understood in depth. In recent years, research has begun to focus on how to improve the efficacy of PD-L1 blockade therapy by regulating the TME. Some strategies aim to increase the infiltration of cytotoxic T cells in the TME or reduce the impact of immunosuppressive cells to enhance the efficacy of immune checkpoint inhibitors. Changing the metabolic properties of the TME may become one of the new strategies to enhance PD-L1 blockade therapy. Studies have shown that by effectively changing the metabolic properties of the TME, the efficacy of PD-L1 blockade therapy may be enhanced. Future studies should focus on uncovering the interaction of various components of the TME and how they jointly influence NSCLC's response to therapy. An in-depth understanding of the impact of TME on NSCLC treatment will help optimize immunotherapy strategies and improve patients' survival rate and quality of life. Future research can focus on studying how the various components of the TME interact and developing new strategies to regulate the TME, thereby expanding new avenues for NSCLC treatment.

Keywords: NSCLC; TME; PD-L1.

1. Introduction

NSCLC is the most common type of lung cancer worldwide, accounting for approximately 85% of all lung cancer cases. As it is often diagnosed at an advanced stage with limited treatment options, it has a serious impact on patient survival. In recent years, immune checkpoint inhibitors, particularly blocking therapies targeting PD-L1, have become an important advancement in the treatment of NSCLC. Such therapies, which recognize and attack tumor cells by activating the body's immune system, have brought about a significant prolongation of survival for some patients. However, while some patients respond favorably to such therapies, the majority exhibit varying degrees of resistance, revealing the need for a deeper understanding of the factors affecting efficacy in order to improve the broad applicability and efficiency of treatments. TME is a complex and dynamically changing factor in tumor growth and progression, which consists of tumor cells, immune cells, extracellular matrix, vascular cells, and a variety of cytokines and chemical signals[1]. Recent studies have shown that TME plays a key role in regulating tumor visibility to the immune system and immune response, thus directly affecting the efficacy of immunotherapy. In particular, certain components within TME are capable of enhancing or inhibiting the efficacy of PD-L1

blocking therapies, which include, but are not limited to, immunosuppressive cells, inflammatory cytokines, and metabolic substances[2].

The aim of this thesis is to explore how specific characteristics of TME affect the response of NSCLC to PD-L1 blockade therapy. In this paper, we hope to reveal the potential mechanisms for improving the efficacy of PD-L1 blockade therapies by comprehensively analyzing the key components and their interactions in TME, and to provide a more scientific basis for personalized treatment of NSCLC patients. In addition, through a deeper understanding of the role of TME, this paper also expects to identify new therapeutic targets, paving the way for the development of more effective combination therapy strategies.

Research progress of the TMEThe TME is the physical, chemical, and biological context for tumor survival, progression, and metastasis. It includes the tumor cells themselves as well as the surrounding supporting cells (e.g., fibroblasts and endothelial cells), immune cells (e.g., T cells, macrophages, and dendritic cells), blood vessels, extracellular matrix (ECM) components, and a variety of lysogenic factors (e.g., growth factors, cytokines, and chemokines.) The formation of the TME is a dynamic process that involves interactions between the tumor cell and its surroundings, and these interactions promote tumor growth and invasion. action promotes tumor growth, inva-

sion, and metastasis, while influencing tumor response to therapy.

The PD-1/PD-L1 pathway is essential for immune evasion by tumors. To avoid immune system surveillance and attack, tumor cells use PD-1 to attach to T cells and decrease their activity. They also upexpress PD-L1 in order to do this. Through this method, PD-L1 inhibiting medication can kill tumor cells and restore T cells' ability to kill. On the other hand, immunosuppressive cells and other TME constituents may also impact the immune system. By targeting PD-L1 or its receptor PD-1 on the surface of tumor cells, PD-L1 blocking therapy reduces the immunosuppression of T cells by tumor cells. This allows T cells to become more active and capable of attacking tumor cells. PD-L1 blockade therapy has emerged as a significant therapeutic option for NSCLC, particularly for those patients whose conventional chemotherapy and radiation therapy are not working. Its effectiveness is not consistent for every patient, though, as it is heavily influenced by a number of TME characteristics.

Studies have focused on exploring how TME affects the effectiveness of PD-L1 blockade therapy. Studies have shown that the degree of immune cell infiltration (ICI) in the TME is an important factor in the response to therapy. For example, highly infiltrated T cells indicate an immunologically active microenvironment, which correlates with a positive response to PD-L1 blockade therapy. In addition, the expression levels of cytokines and chemokines in TME have a significant impact on the therapeutic outcome. Some cytokines, such as IFN- γ , enhance the immune response and promote the efficacy of PD-L1 blockade therapies, whereas others, such as TGF- β , may reduce the efficacy of the treatment by contributing to an immunosuppressive environment.

Other components of the TME, including tumor-associated macrophages (TAMs), tumor-associated fibroblasts (CAFs), and angiogenesis, have also been found to have an impact on the response to PD-L1 blockade therapy. For example, TAMs play a dual role in the TME and may promote or suppress tumor immunity depending on their polarization status (M1-type or M2-type.) M2-type macrophages are commonly associated with an immunosuppressive environment and may reduce the effectiveness of PD-L1 blockade therapy. Similarly, CAFs are able to alter the TME through the secretion of various growth factors and cytokines, thereby affecting immune cell function and tumor response to therapy[4].

In conclusion, the complex composition and dynamics of the TME play a crucial role in the treatment of NSCLC. A deeper understanding of how various aspects of TME affect the efficacy of PD-L1 blocking therapies could provide important information to improve current treatment strategies and develop new combination therapies. This calls for more research to reveal the specific mechanisms

of action of the different factors in TME and how they work together to influence treatment efficacy, ultimately enabling personalized treatment for NSCLC patients.

2. Advances in Research on TME and PD-L1 Blockers

To gain insight into the impact of TME on the effectiveness of PD-L1 blockade therapies, study designs typically utilize a multi-faceted methodological framework that combines basic laboratory research and analysis of existing public databases[5]

The potential impact on the response to PD-L1 blockade therapy was first investigated by assessing the expression levels of specific markers in TME. These markers include, but are not limited to, PD-L1, CD8+ T cells, TGF- β , and other immunosuppressive or activating signaling molecules [6]. Regarding data sources, this paper will utilize two main ways to obtain the required information: first, immunohistochemical staining and flow cytometry of fresh NSCLC samples collected by collaborating laboratories to quantify the expression of immune cells and markers in TME [7]; and second, the use of existing public databases, such as The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), from which large-scale expression data on TME characteristics in NSCLC tumor samples were extracted.

By employing a variety of statistical methods and computational models, initial data analysis will use descriptive statistics to summarize the underlying trends and distribution of marker expression. Further correlation analyses, including Pearson's correlation coefficient and Spearman's rank correlation coefficient, will be used to assess the association between TME marker expression levels and the effect of PD-L1 blockade therapy. In addition, logistic regression models and machine learning techniques (e.g., random forests and support vector machines) will be used to construct predictive models, and the accuracy and validity of the models will be assessed by receiver operating characteristic curves (ROCs) and area under the region (AUCs), which is also a good approach through the use of a variety of statistical methods and computational models[8]. Through these methods, it is hoped that an in-depth understanding of how TME affects the response of NSCLC patients to PD-L1 blockade therapies will be gained, thus providing a scientific basis for improving treatment efficacy and developing new therapeutic strategies.

3. Analysis of Related Results

The relationship between specific markers in the TME of NSCLC patients and the effect of PD-L1 blockade therapy has been analyzed in depth through the methodological framework of this study. The following are the key findings based on laboratory testing and public database anal-

ysis:

3.1 Laboratory Test Results

PD-L1 expression and treatment response (Figure 1): In laboratory-collected NSCLC samples, a significant association between tumor samples with high PD-L1 expression and positive response to PD-L1 blockade therapy was observed by immunohistochemical staining ($p < 0.05$). Specifically, PD-L1 expression levels were significantly higher in patients with a good response to therapy than in those with a poor response to therapy.




Fig. 1 PD-1/PD-L1 interactions for immunotherapy [9].




Fig. 2 Characterisation of infiltrating immune cells in lung squamous cell carcinoma [10].

ICI (Figure 2): Flow cytometry results showed that the degree of CD8+ T-cell infiltration in the TME was positively associated with the effectiveness of PD-L1 blockade therapy ($p < 0.01$). Highly infiltrated samples showed better response to therapy.



Figure 3: The connection between TGF- β and PD-L1 signaling pathways and tumor survival mechanisms [11].

TGF- β level (Figure 3): The tumour-promoting activity of TGF- β within the TME is non-redundant with the PD-L1-mediated tumour evasion mechanism; therefore, simultaneous inhibition of both the TGF- β and PD-L1 pathways may allow for improved overall efficacy compared to blocking either pathway alone.[11]

3.2 Results of Public Database Analysis

Large-scale expression data analysis: Analysis using the TCGA and GEO databases confirmed the consistency of laboratory test results, and the positive correlation between PD-L1 and CD8 expression levels and response to PD-L1 blockade therapy was further validated (Pearson's correlation coefficient > 0.3 , $p < 0.001$).

Predictive model assessment: A tool constructed by machine learning modeling to predict response to PD-L1 blockade therapy showed that the model combining PD-L1 expression, CD8+ T-cell infiltration, and TGF- β levels had high predictive accuracy (AUC = 0.85). This suggests that multifactorial comprehensive analysis is valuable in predicting treatment efficacy.

Impact of TME complexity: Further analysis showed that the presence of other components of TME, such as TAMs and CAFs, also impacted the efficacy of PD-L1 blockade

therapy to varying degrees. This emphasizes the need to consider the overall complexity of TME when considering treatment strategies [11].

4. Discussion

The findings herein reveal the impact of TME characteristics, particularly PD-L1 expression, degree of CD8+ T-cell infiltration, and TGF- β levels, on NSCLC therapeutic strategies, especially the application of PD-L1 blockade therapy. These results emphasize the importance of considering TME characteristics when developing treatment plans. Specifically, high PD-L1 expression and intense CD8+ T-cell infiltration suggest a possible positive response to PD-L1 blockade therapy, whereas high TGF- β levels may predict poor treatment efficacy. Thus, the assessment of TME characteristics can be a powerful tool for predicting treatment response and personalizing treatment regimens.

However, this paper still has some limitations. First, the data from the studies analyzed in this paper were mainly derived from public databases and limited laboratory samples, which may lack a comprehensive portrayal of the complexity of TME. Second, the varying criteria for assessing treatment response may have affected the interpretation of the results. In addition, the present study failed to cover all TME features that may influence the response to PD-L1 blockade therapy, such as the expression of other immunosuppressive molecules and changes in the metabolic milieu.

Given these findings and the limitations that exist, future studies should focus on exploring the impact of TME on NSCLC treatment response more broadly and in depth. These include the use of larger patient sample sets, more precise biomarkers, and advanced bioinformatics tools to validate and extend the current results. In addition, exploring new therapeutic combinations, such as combining PD-L1-blocking therapies with interventions targeting the TGF- β pathway, may provide new strategies for overcoming treatment resistance.

5. Conclusion.

By analyzing the relationship between TME features and the effect of PD-L1 blockade therapy, this study highlights the importance of considering the complexity of the tumor microenvironment in NSCLC treatment. The findings in this paper provide initial insights into how to predict and improve treatment outcomes by evaluating specific mark-

ers in TME. These results underscore the need to develop personalized treatment strategies that not only improve the effectiveness of treatment, but also help avoid ineffective attempts at treatment regimens that are not expected to respond well. Despite the limitations of this study, these findings provide valuable information for future clinical practice and research directions, especially in exploring how to fully leverage TME features to optimize treatment outcomes for NSCLC patients.

References

- [1]Stankovic B, Bjørhovde HAK, Skarshaug R, et al. Immune Cell Composition in Human Non-small Cell Lung Cancer. *Front Immunol.* 2019 Feb 1;9:3101.
- [2]Bejarano L, Jordão MJC, Joyce JA. Therapeutic Targeting of the Tumor Microenvironment. *Cancer Discov.* 2021 Apr;11(4):933-959.
- [3]Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. *Mol Cancer.* 2022 Jan 21;21(1):28.
- [4]Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. *Front Immunol.* 2022 Oct 20;13:954992.
- [5]Olivo Pimentel V, Yaromina A, Marcus D, et al. A novel co-culture assay to assess anti-tumor CD8 T cell cytotoxicity via luminescence and multicolor flow cytometry. *J Immunol Methods.* 2020 Dec;487:112899.
- [6]Gulley JL, Schlom J, Barcellos-Hoff MH, et al. Dual inhibition of TGF- β and PD-L1: a novel approach to cancer treatment. *Mol Oncol.* 2022 Jun;16(11):2117-2134.
- [7]Huang Q, Wu X, Wang Z, et al. The primordial differentiation of tumor-specific memory CD8 T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. *Cell.* 2022 Oct 27;185(22):4049-4066.e25.
- [8]Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. *Cancer Cell.* 2021 Jun 14;39(6):845-865.e7.
- [9]Wu Y, Chen W, Xu ZP, Gu W. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. *Front Immunol.* 2019 Aug 27;10:2022.
- [10]Chen L, Weng Y, Cui X, et al. Comprehensive analyses of a CD8 T cell infiltration related gene signature with regard to the prediction of prognosis and immunotherapy response in lung squamous cell carcinoma. *BMC Bioinformatics.* 2023 Jun 6;24(1):238.
- [11]Gulley JL, Schlom J, Barcellos-Hoff MH, et al. Dual inhibition of TGF- β and PD-L1: a novel approach to cancer treatment. *Mol Oncol.* 2022 Jun;16(11):2117-2134.